BR112012033751A2 - composição de vacina, célula, adjuvante, método de vacinar um paciente contra e. canis e processos para produzir a composição de vacina e o antígeno de e. canis - Google Patents

composição de vacina, célula, adjuvante, método de vacinar um paciente contra e. canis e processos para produzir a composição de vacina e o antígeno de e. canis

Info

Publication number
BR112012033751A2
BR112012033751A2 BR112012033751A BR112012033751A BR112012033751A2 BR 112012033751 A2 BR112012033751 A2 BR 112012033751A2 BR 112012033751 A BR112012033751 A BR 112012033751A BR 112012033751 A BR112012033751 A BR 112012033751A BR 112012033751 A2 BR112012033751 A2 BR 112012033751A2
Authority
BR
Brazil
Prior art keywords
kennels
vaccine composition
vaccinating
adjuvant
processes
Prior art date
Application number
BR112012033751A
Other languages
English (en)
Other versions
BR112012033751B1 (pt
Inventor
Kevin A O'connell
Richard E Corstvet
Rangappa Narayana Ramachandra
Stephen David Gaunt
Terri Lee Wasmoen
Original Assignee
Univ Louisiana State
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Intervet Int Bv filed Critical Univ Louisiana State
Publication of BR112012033751A2 publication Critical patent/BR112012033751A2/pt
Publication of BR112012033751B1 publication Critical patent/BR112012033751B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

composição de vacina, célula, adjuvante, método de vacinar um paciente contra e. canis e processos para produzir a composição de vacina e o antígeno de e. canis. vacina e/ou composições imunogênicas que compreendem uma quantidade de imunização efetiva de um antígeno de e. canis são descritos. além disso, os métodos de imunização ao paciente contra e. canis fornecendo uma vacina e/ou composições imunogênicas também são divulgadas.
BR112012033751-3A 2010-07-02 2011-06-29 Composição de vacina e processo para produzir a composição de vacina BR112012033751B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36096910P 2010-07-02 2010-07-02
US61/360969 2010-07-02
PCT/US2011/042323 WO2012003205A2 (en) 2010-07-02 2011-06-29 Vaccine against ehrlichia canis and associated methods

Publications (2)

Publication Number Publication Date
BR112012033751A2 true BR112012033751A2 (pt) 2016-11-01
BR112012033751B1 BR112012033751B1 (pt) 2021-06-01

Family

ID=44628246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033751-3A BR112012033751B1 (pt) 2010-07-02 2011-06-29 Composição de vacina e processo para produzir a composição de vacina

Country Status (13)

Country Link
US (1) US8790660B2 (pt)
EP (1) EP2588133B1 (pt)
JP (1) JP5933538B2 (pt)
KR (2) KR101858770B1 (pt)
CN (1) CN103200960B (pt)
AU (1) AU2011271495B2 (pt)
BR (1) BR112012033751B1 (pt)
ES (1) ES2661088T3 (pt)
MX (1) MX2013000045A (pt)
PT (1) PT2588133T (pt)
RU (1) RU2603274C2 (pt)
WO (1) WO2012003205A2 (pt)
ZA (1) ZA201300466B (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579945A (en) * 1982-04-29 1986-04-01 Ribi Immunochem Research, Inc. Purification of trehalose dimycolates
CA1216846A (en) * 1982-04-29 1987-01-20 Edgar E. Ribi Purification of trehalose dimycolates and product
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5869335A (en) 1995-08-25 1999-02-09 Regents Of The University Of Minnesota Method of growing rickettsiae in Ixodes scapularis tick cell culture and preparing antigens and vaccines of rickettsiae
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
DE60316189T2 (de) * 2002-11-04 2007-12-20 Research Development Foundation, Carson City P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
PT1765289E (pt) * 2004-07-07 2008-12-05 Statens Seruminstitut Composições e processos para estabilizar formulações de adjuvantes à base de lípidos por meio de glicolípidos
PT2187958T (pt) * 2007-09-11 2017-03-17 Yissum Res Dev Company Of The Hebrew Univ Of Jerusalem Vacina atenuada de erliquiose
KR20100070334A (ko) 2007-09-12 2010-06-25 인터벳 인터내셔널 비.브이. 아나플라즈마타세아 과의 박테리아 종의 배양 방법

Also Published As

Publication number Publication date
AU2011271495B2 (en) 2014-05-29
WO2012003205A2 (en) 2012-01-05
PT2588133T (pt) 2018-03-05
CN103200960A (zh) 2013-07-10
KR20140003371A (ko) 2014-01-09
ZA201300466B (en) 2013-09-25
KR101857938B1 (ko) 2018-05-14
ES2661088T3 (es) 2018-03-27
BR112012033751B1 (pt) 2021-06-01
US20130224247A1 (en) 2013-08-29
WO2012003205A3 (en) 2012-03-01
EP2588133A2 (en) 2013-05-08
KR20180002885A (ko) 2018-01-08
RU2013104173A (ru) 2014-08-10
KR101858770B1 (ko) 2018-05-16
CN103200960B (zh) 2019-04-23
JP2013531677A (ja) 2013-08-08
RU2603274C2 (ru) 2016-11-27
EP2588133B1 (en) 2018-01-17
US8790660B2 (en) 2014-07-29
AU2011271495A1 (en) 2013-02-07
JP5933538B2 (ja) 2016-06-08
MX2013000045A (es) 2013-02-15

Similar Documents

Publication Publication Date Title
CO6331297A2 (es) Composiciones adyuvantes novedosas
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
CA2763359C (en) New human rotavirus strains and vaccines
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
DK2473189T3 (da) Fremgangsmåder til at mindske virucid aktivitet i PCV-2-sammensætninger og PCV-2-sammensætninger med forbedret immunogenicitet.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
BR112013030321A2 (pt) composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2010019262A3 (en) Polyvalent vaccine
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX349119B (es) Vacuna de virus de dengue inactivado.
BR112013025424A2 (pt) processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica
MX346094B (es) Método de administración de vacunas.
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112017028224A2 (pt) composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
BR112013001168A2 (pt) "toxóide, composição farmacêutica, método de produzir uma antitoxina, antitoxina, e, métodos de tratar um indivíduo intoxicado de vacinação contra a intoxicação por uma toxina e de tratar um mamífero intoxicado."
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
BRPI0918226A2 (pt) composição imunogênica, método para produzir uma composição imunogênica, método para elicitar uma resposta imune contra neisseria, uso da composição imunogênica, e, vacina
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
BR112012014689A2 (pt) composição de vacina
WO2011106705A3 (en) Dna-protein vaccination protocols

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2011, OBSERVADAS AS CONDICOES LEGAIS.